Rao Srinivasa P S, Barrett Michael P, Dranoff Glenn, Faraday Christopher J, Gimpelewicz Claudio R, Hailu Asrat, Jones Catherine L, Kelly John M, Lazdins-Helds Janis K, Mäser Pascal, Mengel Jose, Mottram Jeremy C, Mowbray Charles E, Sacks David L, Scott Phillip, Späth Gerald F, Tarleton Rick L, Spector Jonathan M, Diagana Thierry T
Novartis Institute for Tropical Diseases (NITD) , 5300 Chiron Way , Emeryville , California 94608 , United States.
University of Glasgow , University Place , Glasgow G12 8TA , United Kingdom.
ACS Infect Dis. 2019 Feb 8;5(2):152-157. doi: 10.1021/acsinfecdis.8b00298. Epub 2018 Dec 13.
Kinetoplastid parasites have caused human disease for millennia. Significant achievements have been made toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African trypanosomiasis (HAT). Moreover, the sustained decrease in the incidence of HAT has made the prospect of elimination a tantalizing reality. Despite the gains, no new chemical or biological entities to treat kinetoplastid diseases have been registered in more than three decades, and more work is needed to discover safe and effective therapies for patients with Chagas disease and leishmaniasis. Advances in tools for drug discovery and novel insights into the biology of the host-parasite interaction may provide opportunities for accelerated progress. Here, we summarize the output from a gathering of scientists and physicians who met to discuss the current status and future directions in drug discovery for kinetoplastid diseases.
动质体寄生虫引发人类疾病已有数千年历史。在开发治疗利什曼病（特别是在印度次大陆）和人类非洲锥虫病（HAT）的新疗法方面已取得重大进展。此外，HAT发病率的持续下降使消除该疾病的前景成为一个诱人的现实。尽管取得了这些成果，但三十多年来尚无治疗动质体疾病的新化学实体或生物实体注册，仍需要开展更多工作以发现针对恰加斯病和利什曼病患者的安全有效疗法。药物发现工具的进步以及对宿主 - 寄生虫相互作用生物学的新见解可能为加速进展提供机会。在此，我们总结了一次科学家和医生会议的成果，此次会议旨在讨论动质体疾病药物发现的现状和未来方向。
